Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.

@article{Hodgson2014CharacterizationOA,
  title={Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.},
  author={Robert A. Hodgson and Deborra E Mullins and Sherry X. Lu and Mario Guzzi and Xiaoping Zhang and Carina J. Bleickardt and Jack D Scott and Michael A Miller and Andrew W. Stamford and Eric M. Parker and Geoffrey B. Varty},
  journal={European journal of pharmacology},
  year={2014},
  volume={730},
  pages={157-63}
}
Overactivity of the hypothalamic-pituitary-adrenal (HPA) axis has been linked to affective disorders such as anxiety and depression. Dampening HPA activity has, therefore, been considered as a possible means of treating affective disorders. Given the important role of vasopressin in modulating the HPA axis, one strategy has focused on inhibiting activity of… CONTINUE READING